Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
WHWK
Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. (WHWK) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C+
Factor Score
2.5
/ 5.0
Growth
D+
Factor Score
1.7
/ 5.0
Profitability
C
Factor Score
2.2
/ 5.0
Momentum
C-
Factor Score
2.0
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-3.1
EV / EBITDA
-0.1
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-34.0%
Price Return 12M
37.2%
Catalyst Signal
0.00
Market Cap
$180.6M
TTM Revenue
$0.0
Price / Sales
N/A
ROE
-52.0%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D+ (1.7) | C (2.2) | C- (2.0) | C+ (2.6) | C (2.2) |
| 2026-11-08 | A- (3.9) | D+ (1.8) | C (2.2) | C (2.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | B+ (3.7) | D+ (1.7) | C (2.3) | C+ (2.7) | C+ (2.7) | C+ (2.6) |
| 2026-10-25 | B+ (3.7) | D+ (1.7) | C (2.3) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-10-18 | B+ (3.7) | D+ (1.7) | C (2.3) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
Page
1
of
4